{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stock S"],"funding":["Thomas Kirch Stiftung","Universitätsklinik München","Bavarian Center for Cancer Research","Hector Stiftung","Bruno und Helene Jöster Stiftung","Bayerische Forschungsstiftung","Bavarian Ministry for Economical Affairs","Else Kröner-Fresenius-Stiftung","Ludwig-Maximilians-Universität München","SFB-TRR 338","German Excellence Initiative","Wilhelm Sander-Stiftung","European Research Council","Deutsche Forschungsgemeinschaft","Deutsche Krebshilfe","Bavarian Elite Graduate Training Network","Elitenetzwerk Bayern","Fritz-Bender-Stiftung","European Union","Deutschen Konsortium für Translationale Krebsforschung","Ernst-Jung-Stiftung","Marie Sklodowska-Curie Program Training Network","Melanoma Research Alliance","José Carreras Leukämie-Stiftung","Bundesministerium für Bildung und Forschung","Go-Bio Initiative"],"pagination":["100"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11024081"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73(6)"],"pubmed_abstract":["In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. As the CAR construct architecture can differentially impact performance and efficacy, the optimal construction of a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying the constituents of the CAR structure known to impact performance could shed light on how to improve established anti-BCMA CAR constructs. CD8TM.41BBIC-based anti-BCMA CAR vectors with either a long linker or a short linker between the light and heavy scFv chain, CD28TM.41BBIC-based and CD28TM.CD28IC-ba"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma."],"pmcid":["PMC11024081"],"funding_grant_id":["756017","101100460","101124203"],"pubmed_authors":["Endres S","Cordas Dos Santos DM","Theurich S","Subklewe M","Kobold S","Majed L","Stock S","Grunmeier R","Dorr J","Fertig L","von Bergwelt-Baildon M","Gottschlich A","Menkhoff VD","Rejeski K","Markl F"],"additional_accession":[]},"is_claimable":false,"name":"Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.","description":"In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. As the CAR construct architecture can differentially impact performance and efficacy, the optimal construction of a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying the constituents of the CAR structure known to impact performance could shed light on how to improve established anti-BCMA CAR constructs. CD8TM.41BBIC-based anti-BCMA CAR vectors with either a long linker or a short linker between the light and heavy scFv chain, CD28TM.41BBIC-based and CD28TM.CD28IC-ba","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T21:55:38.646Z","creation":"2025-04-06T03:18:01.832Z"},"accession":"S-EPMC11024081","cross_references":{"pubmed":["38630291"],"doi":["10.1007/s00262-024-03688-4"]}}